Human chorionic gonadotropin in oncology: a matter of tight (bio)marking

Articles in the same Issue

1. Frontmatter
2. Editorial
3. Progress in understanding the use of human chorionic gonadotropin as a tumor marker
4. Reviews
5. Biomarkers for prostate cancer: prostate-specific antigen and beyond
6. Gut microbiome investigation in celiac disease: from methods to its pathogenetic role
7. Opinion Papers
8. Understanding and managing interferences in clinical laboratory assays: the role of laboratory professionals
9. A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer
10. EFLM Opinion Paper
11. Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation
12. Guidelines and Recommendations
13. An updated protocol based on CLSI document C37 for preparation of off-the-clot serum from individual units for use alone or to prepare commutable pooled serum reference materials
14. General Clinical Chemistry and Laboratory Medicine
15. Highly accurate and explainable detection of specimen mix-up using a machine learning model
16. Impact of delta check time intervals on error detection capability
17. Effect of long-term frozen storage and thawing of stool samples on faecal haemoglobin concentration and diagnostic performance of faecal immunochemical tests
18. A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PlGF ratio and NT-proBNP as biomarkers
19. Macro vitamin B12: an underestimated threat
20. Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients
21. High frequency of anti-parietal cell antibody (APCA) and intrinsic factor blocking antibody (IFBA) in individuals with severe vitamin B12 deficiency – an observational study in primary care patients
22. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients
23. Cancer Diagnostics
24. How comparable are total human chorionic gonadotropin (hCGt) tumour markers assays?
25. Diabetes
26. Measurement accuracy of two professional-use systems for point-of-care testing of blood glucose
27. Letters to the Editor
28. Human chorionic gonadotropin in oncology: a matter of tight (bio)marking
29. More robust analytical evidence should support the selection of human chorionic gonadotropin assays for oncology application
30. Letter in reply to the letter to the editor of Ferraro S and Panteghini M with the title “More robust analytical evidence should support the selection for human chorionic gonadotropin assays for oncology application”
31. Definition of analytical quality specifications for serum total folate measurements using a simulation outcome-based model
32. Alarmed by misleading interference in free T3 and free T4 assays: a new case of anti-streptavidin antibodies
33. A root cause analysis of ‘falsely elevated’ oxygen saturation: investigation of pneumatic tube transport and differences between estimated and measured saturation in a critical patient population
34. The chaos of serologic markers in interstitial pneumonia with autoimmune features can be corrected by the laboratory physician
35. Vitamin A and E gender and age stratification in adults
36. Detection of monoclonal B-lymphocytosis: interest of cellular population data and CytoDiff™ analysis
37. Urinary reference intervals for gadolinium in individuals without recent exposure to gadolinium-based contrast agents
38. Molecular diagnosis of toxoplasmosis: evaluation of automated DNA extraction using eMAG^® (bioMérieux) on buffy coat, cerebrospinal and bronchoalveolar lavage fluids
39. Retraction
40. Retraction of: The Effect of a Gender Difference in the Apolipoprotein E Gene DNA Polymorphism on Serum Lipid Levels in a Serbian Healthy Population